Marshall Wace
CRL icon

Marshall Wace’s Charles River Laboratories CRL Stock Holding History

Marshall Wace’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.8M Buy
342,995
+193,344
+129% +$34.4M 0.06% 258
2026
Q1 		$25.8M Buy
149,651
+25,458
+20% +$4.72M 0.03% 605
2025
Q4 		$24.8M Sell
124,193
-13,917
-10% -$2.52M 0.02% 559
2025
Q3 		$21.6M Buy
138,110
+124,038
+881% +$19.7M 0.02% 622
2025
Q2 		$2.14M Sell
14,072
-23,862
-63% -$3.18M ﹤0.01% 1527
2025
Q1 		$5.71M Buy
37,934
+16,326
+76% +$2.74M 0.01% 998
2024
Q4 		$3.99M Sell
21,608
-287,451
-93% -$55.4M ﹤0.01% 1160
2024
Q3 		$60.9M Sell
309,059
-516,846
-63% -$107M 0.07% 234
2024
Q2 		$171M Buy
825,905
+163,056
+25% +$36.9M 0.23% 73
2024
Q1 		$180M Buy
+662,849
New +$158M 0.27% 64
2023
Q4 		– Sell
-121,479
Closed -$23.8M – 2231
2023
Q3 		$23.8M Sell
121,479
-305,047
-72% -$62.6M 0.05% 384
2023
Q2 		$89.7M Sell
426,526
-528,388
-55% -$105M 0.18% 122
2023
Q1 		$193M Buy
954,914
+80,141
+9% +$18.2M 0.41% 40
2022
Q4 		$191M Buy
874,773
+319,095
+57% +$69.7M 0.43% 38
2022
Q3 		$109M Buy
555,678
+215,372
+63% +$46.5M 0.24% 78
2022
Q2 		$72.8M Buy
340,306
+167,447
+97% +$40.9M 0.15% 138
2022
Q1 		$49.1M Sell
172,859
-281,936
-62% -$86.9M 0.09% 233
2021
Q4 		$171M Buy
454,795
+152,258
+50% +$59.2M 0.32% 47
2021
Q3 		$125M Buy
302,537
+19,810
+7% +$8.23M 0.52% 19
2021
Q2 		$105M Sell
282,727
-634,329
-69% -$212M 0.47% 31
2021
Q1 		$266M Buy
917,056
+64,142
+8% +$17.8M 1.22% 6
2020
Q4 		$213M Buy
852,914
+39,637
+5% +$9.44M 1.15% 14
2020
Q3 		$184M Buy
813,277
+721,829
+789% +$150M 1.18% 12
2020
Q2 		$15.9M Buy
+91,448
New +$14.6M 0.11% 194
2020
Q1 		– Sell
-201,547
Closed -$30.8M – 1681
2019
Q4 		$30.8M Buy
201,547
+80,303
+66% +$11.1M 0.21% 113
2019
Q3 		$16M Buy
121,244
+51,461
+74% +$6.9M 0.13% 190
2019
Q2 		$9.9M Buy
69,783
+62,299
+832% +$8.45M 0.08% 281
2019
Q1 		$1.09M Buy
7,484
+3,414
+84% +$449K 0.01% 901
2018
Q4 		$461K Sell
4,070
-43,432
-91% -$5.44M ﹤0.01% 1130
2018
Q3 		$6.39M Buy
+47,502
New +$5.86M 0.05% 407
2017
Q1 		– Sell
-469,045
Closed -$35.7M – 393
2016
Q4 		$35.7M Buy
469,045
+428,573
+1,059% +$32.5M 0.24% 118
2016
Q3 		$3.37M Sell
40,472
-67,696
-63% -$5.67M 0.02% 488
2016
Q2 		$8.92M Buy
108,168
+51,604
+91% +$4.25M 0.08% 270
2016
Q1 		$4.29M Buy
56,564
+41,926
+286% +$3.1M 0.04% 378
2015
Q4 		$1.18M Sell
14,638
-18,833
-56% -$1.36M 0.01% 676
2015
Q3 		$2.13M Sell
33,471
-165,356
-83% -$11.9M 0.03% 443
2015
Q2 		$14M Buy
+198,827
New +$14.7M 0.18% 136

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Marshall Wace's CRL Position: Q2 2026 in Review

Marshall Wace increased its Charles River Laboratories (CRL) stake by 129% in Q2 2026, buying an estimated $34.4M and bringing the position to 342,995 shares worth $77.8M. The position accounts for 0.06% of the portfolio, ranked #258.

Marshall Wace first reported a position in CRL in Q2 2015 and has held it in 37 quarters since. The position peaked at $266M in Q1 2021. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Marshall Wace held 342,995 shares of Charles River Laboratories worth $77.8M as of Q2 2026.
  • Marshall Wace bought 193,344 Charles River Laboratories shares in Q2 2026, an estimated $34.4M.
  • Charles River Laboratories made up 0.06% of Marshall Wace's portfolio in Q2 2026, its #258 holding.
  • Marshall Wace first reported a position in Charles River Laboratories in Q2 2015 and has held it in 37 quarters since.
  • Marshall Wace's Charles River Laboratories position peaked at $266M in Q1 2021.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.